Novartis Talks Up Potential Blockbusters
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis used its second-quarter results to flag the blockbuster potential of three drugs: recently-approved heart failure drug Entresto, first-to-be approved IL-17a blocker Cosentyx - as well as oncology drug Promacta, which it bought from GSK earlier this year.